Gregg Gilbert
Stock Analyst at Truist Securities
(2.25)
# 2,772
Out of 4,981 analysts
84
Total ratings
53.7%
Success rate
5.38%
Average return
Main Sectors:
Stocks Rated by Gregg Gilbert
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DHT DHT Holdings | Maintains: Buy | $14 → $17 | $12.75 | +33.39% | 2 | Feb 16, 2024 | |
| COLL Collegium Pharmaceutical | Maintains: Buy | $31 → $37 | $35.06 | +5.53% | 1 | Jan 4, 2024 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Buy | $84 | $46.42 | +80.96% | 9 | Sep 15, 2023 | |
| LLY Eli Lilly and Company | Maintains: Buy | $430 → $525 | $749.00 | -29.91% | 10 | Jul 20, 2023 | |
| EOLS Evolus | Maintains: Buy | $11 → $13 | $6.64 | +95.78% | 2 | Mar 4, 2022 | |
| NVCR NovoCure | Upgrades: Buy | n/a | $12.66 | - | 10 | Jan 20, 2022 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $93 | $81.24 | +14.48% | 8 | Jun 7, 2021 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $38 → $48 | $16.93 | +183.52% | 2 | Feb 2, 2021 | |
| CHRS Coherus Oncology | Initiates: Buy | $26 | $1.27 | +1,947.24% | 1 | Apr 17, 2020 | |
| MTNB Matinas BioPharma Holdings | Initiates: Buy | $150 | $1.79 | +8,279.89% | 1 | Jan 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $93 → $78 | $21.79 | +257.96% | 17 | Aug 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $76 → $78 | $146.48 | -46.75% | 5 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $18 | $18.96 | -5.04% | 6 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $175 | $125.23 | +39.75% | 6 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $65 → $66 | $217.85 | -69.70% | 4 | Jul 17, 2017 |
DHT Holdings
Feb 16, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $12.75
Upside: +33.39%
Collegium Pharmaceutical
Jan 4, 2024
Maintains: Buy
Price Target: $31 → $37
Current: $35.06
Upside: +5.53%
Bristol-Myers Squibb Company
Sep 15, 2023
Reiterates: Buy
Price Target: $84
Current: $46.42
Upside: +80.96%
Eli Lilly and Company
Jul 20, 2023
Maintains: Buy
Price Target: $430 → $525
Current: $749.00
Upside: -29.91%
Evolus
Mar 4, 2022
Maintains: Buy
Price Target: $11 → $13
Current: $6.64
Upside: +95.78%
NovoCure
Jan 20, 2022
Upgrades: Buy
Price Target: n/a
Current: $12.66
Upside: -
Merck & Co.
Jun 7, 2021
Maintains: Buy
Price Target: $96 → $93
Current: $81.24
Upside: +14.48%
Arcutis Biotherapeutics
Feb 2, 2021
Maintains: Buy
Price Target: $38 → $48
Current: $16.93
Upside: +183.52%
Coherus Oncology
Apr 17, 2020
Initiates: Buy
Price Target: $26
Current: $1.27
Upside: +1,947.24%
Matinas BioPharma Holdings
Jan 24, 2020
Initiates: Buy
Price Target: $150
Current: $1.79
Upside: +8,279.89%
Aug 10, 2018
Downgrades: Hold
Price Target: $93 → $78
Current: $21.79
Upside: +257.96%
Feb 16, 2018
Maintains: Hold
Price Target: $76 → $78
Current: $146.48
Upside: -46.75%
Feb 9, 2018
Maintains: Hold
Price Target: $20 → $18
Current: $18.96
Upside: -5.04%
Aug 9, 2017
Maintains: Buy
Price Target: $178 → $175
Current: $125.23
Upside: +39.75%
Jul 17, 2017
Maintains: Hold
Price Target: $65 → $66
Current: $217.85
Upside: -69.70%